Baudax Bio, Inc. (BXRXQ) Research

Baudax Bio, Inc., a biopharmaceutical company established in Malvern, Pennsylvania in 2019, specializes in developing and commercializing therapeutic solutions for hospital and acute care environments. Their marketed product, ANJESO (meloxicam injection), is utilized for managing moderate to severe pain, either independently or in conjunction with other non-NSAID analgesics. The company’s pipeline includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) currently in Phase II clinical trials, and BX2000, an ultra-short-acting NMB, which is in Phase I clinical assessment. Furthermore, Baudax Bio is advancing a proprietary agent to reverse neuromuscular blockade, with BX3000, another NMB reversal agent, undergoing preclinical studies. On February 22, 2024, Baudax Bio, Inc. initiated voluntary Chapter 11 reorganization proceedings in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.

Open Baudax Bio, Inc. (BXRXQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.